GENNIEFY
Market News
Latest financial news and analysis from global markets
NVDA
3 Stocks Smart Quantum Computing Investors Are Buying
Quantum computing investing isn't front and center.
NEE
This Top Nuclear Energy Dividend Stock Could Turn $1,000 Into a Lifetime Income Stream
NextEra Energy is about to become the second-largest nuclear energy company in the United States.
D
This Top Nuclear Energy Dividend Stock Could Turn $1,000 Into a Lifetime Income Stream
NextEra Energy is about to become the second-largest nuclear energy company in the United States.
NVDA
Why EPAM Systems Stock Rocketed Higher This Week
There's more than one reason behind this software stock's rise.
NVDA
Walmart Earnings, Warsh Swearing In: What to Watch for Rest of the Week
Wednesday brought a bevy of tech news, from the posting of SpaceX's IPO filing to updates on Nvidia, Anthropic and OpenAI. For the rest of the week, focus turns to the American consumer with Walmart earnings and Friday's swearing in of Kevin Warsh as the new Federal Reserve chair.
WMT
Walmart Earnings, Warsh Swearing In: What to Watch for Rest of the Week
Wednesday brought a bevy of tech news, from the posting of SpaceX's IPO filing to updates on Nvidia, Anthropic and OpenAI. For the rest of the week, focus turns to the American consumer with Walmart earnings and Friday's swearing in of Kevin Warsh as the new Federal Reserve chair.
NVDA
What NVIDIA (NVDA)'s Record Q1 Payouts and US$80 Billion Buyback Mean For Shareholders
NVIDIA reported past first-quarter results for the period ended April 26, 2026, with revenue of US$81.62 billion and net income of US$58.32 billion, and announced a sharply higher dividend plus an US$80 billion share repurchase authorization. Despite this very large profit and cash generation, early market reaction was muted as investors weighed the sustainability of AI infrastructure demand and the impact of NVIDIA’s new reporting structure. We’ll now examine how these record earnings and...
GOOGL
OpenAI Faces IPO Unknowns Even After Victory Over Elon Musk
(Bloomberg) -- Elon Musk’s legal battle against OpenAI has hung over the ChatGPT maker for more than two years, threatening to unravel its restructuring as a for-profit business and undermine its plans to go public.Most Read from BloombergSpot the Difference: Putin Gets Trump Treatment From Xi in ChinaModi’s Toffee Gift to Meloni Ignites Rally in Wrong Indian StockSpaceX Shows $4.3 Billion Loss as Musk Targets Record IPOIran Threatens to Retaliate Beyond Middle East If US AttacksNvidia Tells Ske
ROKU
1 Internet Stock Worth Your Attention and 2 Facing Headwinds
Consumer internet businesses are redefining how people engage with the world by giving them instant connectivity and convenience. This influence cuts both ways though because they have high exposure to the ups and downs of consumer spending, and the market seems to believe the tide is turning in the wrong direction - over the past six months, the industry has tumbled by 13.2%. This drawdown is a noticeable divergence from the S&P 500’s 11.6% return.
BTCUSDT
Glassnode Finds 20% of Bitcoin Quantum-Exposed by Behavior, Not Code
Glassnode finds 4.12M BTC quantum-exposed by wallet behavior, more than double Bitcoin's structural script exposure.
SHOP
RingCentral AIR Expansion And Growing Adoption Meet Valuation Gap Narrative
RingCentral (NYSE:RNG) has expanded its AI Receptionist (AIR) with new integrations for Shopify, Calendly, and WhatsApp. The update introduces automatic multi language detection and offers AIR as a standalone product at a lower entry price. RingCentral reports that AIR is now used by more than 11,800 businesses, signaling growing adoption across industries. For investors watching NYSE:RNG, this product update comes as the stock trades around $43.51, with returns of 12.3% over the past week,...
PFE
Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story
Pfizer and its partners have granted Rigel Pharmaceuticals an exclusive license to commercialize VEPPANU (vepdegestrant), the first FDA approved oral PROTAC for advanced breast cancer. The agreement follows Phase 3 data that support clinical benefit in a difficult to treat patient group and inclusion of VEPPANU in NCCN breast cancer guidelines. The deal introduces a new commercialization pathway for VEPPANU and adds another partnership driven revenue channel for Pfizer. For investors...